108 related articles for article (PubMed ID: 14619486)
1. [Examination of therapy using trastuzumab in patients with metastatic breast carcinoma].
Nohara T; Iwamoto M; Kobayashi T; Lee SW; Sumiyoshi K; Tanigawa N
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1651-4. PubMed ID: 14619486
[TBL] [Abstract][Full Text] [Related]
2. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
3. [Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer].
Suzuki M; Kimijima I; Ishii M
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1519-23. PubMed ID: 19755824
[TBL] [Abstract][Full Text] [Related]
4. [Markedly effective regimen using bi-weekly trastuzumab and paclitaxel in an advanced breast cancer with multiple liver metastases].
Rai Y; Takahama T; Sagara Y; Sagara Y; Matsuyama Y; Ando M; Sagara Y; Ooi Y
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1297-300. PubMed ID: 16969028
[TBL] [Abstract][Full Text] [Related]
5. [Effective combination chemotherapy using weekly trastuzumab and paclitaxel in the treatment of a recurrent breast cancer patient with liver metastases].
Tohnosu N; Kobayashi Y; Saito T; Shimizu T; Natsume T; Tanaka H; Maruyama T; Watanabe Y
Gan To Kagaku Ryoho; 2003 Jul; 30(7):989-92. PubMed ID: 12894716
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
[TBL] [Abstract][Full Text] [Related]
9. [A case of HER2 overexpressing recurrent breast cancer treated clinically showing a complete response to trastuzumab/paclitaxel combination therapy].
Mizuno Y; Chin K; Ando N; Oike E
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1293-6. PubMed ID: 16969027
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
11. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
12. [Metastatic breast cancer treated with trastuzumab and paclitaxel--a case report with clinically complete response].
Yoshida T; Horiguchi J; Koibuchi Y; Kanoh T; Iijima K; Yoshida M; Kikuchi M; Takata D; Oyama T; Iino Y; Morishita Y
Gan To Kagaku Ryoho; 2004 Jun; 31(6):907-10. PubMed ID: 15222110
[TBL] [Abstract][Full Text] [Related]
13. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
[TBL] [Abstract][Full Text] [Related]
14. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M
Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
Leyland-Jones B; Gelmon K; Ayoub JP; Arnold A; Verma S; Dias R; Ghahramani P
J Clin Oncol; 2003 Nov; 21(21):3965-71. PubMed ID: 14507946
[TBL] [Abstract][Full Text] [Related]
16. [Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report].
Sakurai T; Jinta E; Suzuma T; Yoshimura G; Umemura T; Sakurai T
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1703-6. PubMed ID: 23152023
[TBL] [Abstract][Full Text] [Related]
17. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Ruiz M; Salvador J; Bayo J; Lomas M; Moreno A; Valero M; Bernabé R; Vicente D; Jiménez J; Lopez-Ladrón A
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1085-90. PubMed ID: 18365200
[TBL] [Abstract][Full Text] [Related]
18. [A case of liver metastasis of breast cancer responding to trastuzumab plus weekly paclitaxel chemotherapy maintaining CR for 30 months].
Nagahisa Y; Imai S; Yamaguchi K; Okabe M; Tsuruta A; Kawamoto K; Niwano M; Sano K; Park T; Yoshida Y; Ito T; Ogasahara K
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1501-3. PubMed ID: 17876156
[TBL] [Abstract][Full Text] [Related]
19. Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
Poncet B; Bachelot T; Colin C; Ganne C; Jaisson-Hot I; Orfeuvre H; Peaud PY; Jacquin JP; Salles B; Tigaud JD; Mechin-Cretinon I; Marechal F; Fournel C; Trillet-Lenoir V
Am J Clin Oncol; 2008 Aug; 31(4):363-8. PubMed ID: 18845995
[TBL] [Abstract][Full Text] [Related]
20. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
